Table 4. Clinical and laboratory features of 53 ‘young' adults (age⩽65 years) with chronic myelomonocytic leukemia that underwent allogeneic stem cell transplantation and their outcomes.
| Variables | All N=53 | Myeloablative conditioning N=14 (33%) | Reduced intensity conditioning N=28 (67%) | P-value |
|---|---|---|---|---|
| Age | 52 (18–65) | 51 (27–62) | 48 (18–65) | 0.7 |
| Sex | 32 (60%) | 8 (57%) | 8 (57%) | 1.0 |
| WHO morphological subtype; n (%) | ||||
| CMML-1 | 36 (68%) | 8 (57%) | 21 (75%) | 0.2 |
| CMML-2 | 17 (32%) | 6 (43%) | 7 (25%) | — |
| ASXL1 ‘N' evaluable= 25 | 7 (28%) | 3 (33%) | 1 (14%) | 0.4 |
| SRSF2 ‘N' evaluable=24 | 8 (33%) | 4 (44%) | 2 (29%) | 0.5 |
| Mayo-French cytogenetic risk stratification | — | — | — | 0.7 |
| Low | 40 (75%) | 11 (79%) | 19 (68%) | — |
| Intermediate | 12 (23%) | 3 (21%) | 8 (29%) | — |
| High | 1 (2%) | — | 1 (3%) | — |
| Mayo Molecular Model risk categorization ‘N' evaluable=25 | ||||
| Low | 1 (4%) | 0 (0%) | 1 (14%) | 0.5 |
| Intermediate-1 | 8 (32%) | 2 (22%) | 1 (14%) | — |
| Intermediate-2 | 5 (20%) | 3 (33%) | 1 (14%) | — |
| High | 11 (44%) | 4 (44%) | 4 (57%) | — |
| Mayo-French cytogenetic risk stratification ‘N' evaluable=53 | ||||
| Low | 40(75%) | 11 (79%) | 19 (68%) | 0.7 |
| Intermediate | 12 (23%) | 3 (21%) | 8 (29%) | — |
| High | 1 (2%) | 0 (0%) | 1 (3%) | — |
| Graft source ‘N' evaluable=40 | ||||
| Matched sibling donor | 20 (50%) | 7 (54%) | 12 (46%) | 0.5 |
| Matched unrelated donor | 13 (32%) | 4 (31%) | 9 (35%) | — |
| Mismatched unrelated donor | 4 (10%) | 1 (8%) | 3 (11%) | — |
| Umbilical cord blood units | 1 (3%) | 1 (8%) | 0 (0%) | — |
| Haploidentical donor | 2 (5%) | 0 (0%) | 2 (8%) | — |
| Acute GVHD ‘N' evaluable=40 | 19 (47%) | 10 (76%) | 9 (35%) | 0.01 |
| Chronic GVHD ‘N' evaluable=43 | 29 (67%) | 8 (57%) | 21 (75%) | 0.2 |
| Outcome of transplant ‘N' evaluable=43 | ||||
| CR | 24 (56%) | 8 (61%) | 15 (55%) | 0.4 |
| Relapse | 10 (23%) | 1 (8%) | 7 (26%) | — |
| Death | 8 (19%) | 4 (31%) | 4 (15%) | — |
| Failure | 1 (2%) | 0 (0%) | 1 (4%) | — |
Abbreviations: ASXL1, additional sex combs 1 gene; CMML, chronic myelomonocytic leukemia; CR, complete remission; GVHD, graft versus host disease; SRSF2, serine/arginine-rich splicing factor 2; WHO, World Health Organization. Bold entries signify statistically significant P-values (i.e. P<0.05).